Nick Hart serves as President for HemCon Medical Technologies. Hart joined the company in 2008 in the role of chief financial officer, following the acquisition of Alltracel Pharmaceuticals Plc where he also was chief financial officer. Prior to this, Hart worked in the life sciences sector for over 20 years, and in the earlier part of his career within a number of manufacturing organizations.
Before joining Alltracel, Hart was chief financial officer of Smart Holograms Ltd., a company developing devices for disease diagnosis and management, and for Bioscience Managers Ltd., an international life sciences corporate finance and advisory practice, advising companies on M&A, strategy, finance and licensing transactions. Prior to those appointments, he was chief financial officer, chief operating officer and acting chief executive officer of Cantab Pharmaceuticals Plc. There, he had numerous financial, corporate and strategic accomplishments including managing Cantab’s IPOs on NASDAQ and the LSE and subsequently leading Cantab’s merger with Xenova Group Plc. Within life sciences, Hart has also worked for BOC Healthcare and Servier, a French pharmaceutical company.
A British citizen, Hart received his bachelor’s degree in Economics and Statistics from Kingston University, London. He is a fellow member of the Institute of Chartered Management Accountants.
Simon J. McCarthy, Ph.D.
Chief Scientist |
Simon McCarthy serves as HemCon’s Chief Scientist and is responsible for the research of new products and devices to control bleeding and promote wound repair.
McCarthy received his undergraduate degree in chemistry and his Ph.D. in polymer chemistry from Monash University in Melbourne, Australia. He has authored or co-authored more than 20 scientific papers and is a co-holder of six patents on polyurethanes and polyesters for biomedical applications.
Keith Real, Ph.D.
Executive Vice President, Research and Development |
An accomplished executive, scientist and scholar, Keith Real is HemCon’s Executive Vice President of Research and Developement. He is responsible for the research and development of new technology platforms and early stage products. Before joining HemCon, he served as Chief Scientific Officer for the Alltracel Group, directing the company’s research and development and technology development divisions. Real was also appointed as Chief Scientific Officer at Nanopeutics s.r.o., Alltracel’s nanotechnology joint venture with Elmarco. From 1999-2004, he had also worked with Alltracel in a contract research capacity. Real has worked as a consultant to other businesses and has served as a new biomedical technology appraiser for government agencies. He has also managed projects for international consortiums of collaborators including universities, regulators, government departments and private companies.
Real obtained a Diploma in Business Finance from the Irish Management Institute, a Bachelor of Science degree in Biochemistry from University College Dublin, and a Ph.D. in Biochemistry from University College Dublin.